News

Donepezil Safe, Effective In African Americans


 

SAN DIEGO — Donepezil is safe and effective in African Americans with mild to moderate Alzheimer's disease, a 12-week open-label study showed.

The finding is important because African Americans are underrepresented in clinical trials even though they have a higher risk of developing Alzheimer's disease, compared with whites, Patrick Griffith, M.D., said during a poster session at the annual meeting of the American Association for Geriatric Psychiatry.

In addition, this is the first Alzheimer's trial to use the Fuld Object Memory Evaluation (FOME), which is thought to provide a culturally unbiased evaluation of memory. “The test has been validated in African Americans, and it operates independent of educational level or [social background].”

Dr. Griffith, chief of the division of neurology at Morehouse School of Medicine, Atlanta, said in an interview. “It relies on touch and vision. We may have a measuring tool for future clinical trials that will avoid previous reports of educational or cultural bias.” Dr. Griffith and his associates enrolled 125 community-dwelling African Americans aged 51–98 from 30 sites in the United States with a clinical diagnosis of mild to moderate Alzheimer's disease and Mini-Mental State Examination (MMSE) scores of 10–26. The patients received donepezil (Aricept) 5 mg/day at the conclusion of their baseline visit; the dose was increased to 10 mg/day after 4 weeks—according to clinician judgment.

At weeks 4, 8, and 12, the investigators administered the FOME, the MMSE, and the Clinician Interview-Based Impression of Change with Caregiver Input (CIBIC-plus). From baseline to week 12, patients showed significant improvement on the FOME storage and retrieval scores, the MMSE scores, and the CIBIC-plus scores.

The most common treatment-emergent adverse events were diarrhea, hypertension, and urinary tract infection, and the incidences were similar to those reported previously in patients with mild to moderate Alzheimer's. Lab results were unremarkable. Pfizer Inc., which manufactures donepezil, supported the study.

Recommended Reading

Bipolar Elderly Need Careful Treatment
MDedge Family Medicine
Home Visits and Phone Follow-Up Improve Depression in Elderly
MDedge Family Medicine
Black Caregivers of Alzheimer's Patients Less Likely to Be Depressed
MDedge Family Medicine
Combo Approach Eases Pelvic Floor Dysfunction
MDedge Family Medicine
Resistant Enterococci Behind Elders' Urinary Tract Infections
MDedge Family Medicine
New Drug for Overactive Bladder Lacks Cognitive Side Effects
MDedge Family Medicine
VA Study Compares Epilepsy Treatments in Elderly : Newer antiepileptic agents were better tolerated and more effective than the older carbamazepine.
MDedge Family Medicine
Urge Warfarin Users to Avoid Cranberry Juice
MDedge Family Medicine
New-Onset Epilepsy Can Resemble Dementia in Some Elderly Patients
MDedge Family Medicine
Newer Antiepileptics May Worsen Osteoporosis
MDedge Family Medicine